{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:41:26Z","timestamp":1791132086192,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/fpc.0b013e328350012b","type":"journal-article","created":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T04:37:44Z","timestamp":1326343064000},"page":"198-205","source":"Crossref","is-referenced-by-count":73,"title":["MicroRNA profiling in K-562 cells under imatinib treatment"],"prefix":"10.1097","volume":"22","author":[{"given":"Eleonora","family":"Turrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierk","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Laechelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Diewock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/156800911793743637","article-title":"Current treatment concepts of CML.","volume":"11","author":"Leitner","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"R2-5-20210213","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia.","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett"},{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia.","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1634\/theoncologist.12-12-1390","article-title":"Imatinib.","volume":"12","author":"De Kogel","year":"2007","journal-title":"Oncologist"},{"key":"R7-5-20210213","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.","volume":"1587","author":"Hegedus","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"R9-5-20210213","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers.","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R11-5-20210213","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R12-5-20210213","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"R13-5-20210213","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ijc.24782","article-title":"Role of microRNA in anticancer drug resistance.","volume":"126","author":"Zheng","year":"2010","journal-title":"Int J Cancer"},{"key":"R14-5-20210213","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-08-0021","article-title":"Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.","volume":"7","author":"Kovalchuk","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R15-5-20210213","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","article-title":"Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1P-glycoprotein expression in human cancer cells.","volume":"76","author":"Zhu","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R16-5-20210213","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-09-0292","article-title":"Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.","volume":"8","author":"To","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R17-5-20210213","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood-2008-01-136218","article-title":"The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells.","volume":"113","author":"Zhao","year":"2009","journal-title":"Blood"},{"key":"R18-5-20210213","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"R19-5-20210213","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/BJ20082131","article-title":"Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.","volume":"420","author":"Park","year":"2009","journal-title":"Biochem J"},{"key":"R20-5-20210213","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/tpj.2010.20","article-title":"Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.","volume":"11","author":"Laechelt","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"Suppl 1","key":"R21-5-20210213","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.leukres.2003.10.007","article-title":"Molecular mechanisms of resistance of leukemia to imatinib mesylate.","volume":"28","author":"Tauchi","year":"2004","journal-title":"Leuk Res"},{"key":"R22-5-20210213","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.","volume":"359","author":"Von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"R23-5-20210213","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"R24-5-20210213","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1124\/mol.108.054163","article-title":"MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRPABCG2) in human cancer cells.","volume":"75","author":"Pan","year":"2009","journal-title":"Mol Pharmacol"},{"key":"R28-5-20210213","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cell.2010.02.020","article-title":"Preview. MicroRNAs: from decay to decoy.","volume":"140","author":"Beitzinger","year":"2010","journal-title":"Cell"},{"key":"R29-5-20210213","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01213011-201203000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:28:50Z","timestamp":1786048130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-201203000-00005"}},"subtitle":["influence of miR-212 and miR-328 on ABCG2 expression"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328350012b","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}